CIRCASSIA LTD has a total of 218 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 1997. It filed its patents most often in United Kingdom, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SCHENK DALE B, RUOSLAHTI ERKKI and GRANDI GUIDO.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 36 | |
#2 | EPO (European Patent Office) | 28 | |
#3 | United States | 21 | |
#4 | Australia | 19 | |
#5 | WIPO (World Intellectual Property Organization) | 19 | |
#6 | China | 15 | |
#7 | Canada | 11 | |
#8 | Hong Kong | 9 | |
#9 | Israel | 8 | |
#10 | Japan | 8 | |
#11 | Mexico | 8 | |
#12 | Brazil | 6 | |
#13 | Singapore | 6 | |
#14 | Republic of Korea | 5 | |
#15 | New Zealand | 5 | |
#16 | EAPO (Eurasian Patent Organization) | 4 | |
#17 | South Africa | 4 | |
#18 | Chile | 2 | |
#19 | India | 2 | |
#20 | Hungary | 1 | |
#21 | Slovenia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Foods and drinks | |
#6 | Chemical engineering | |
#7 | Surface technology and coating | |
#8 | Machines |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Medical purpose containers | |
#6 | Microorganisms | |
#7 | Enzymes | |
#8 | Separation | |
#9 | Single-crystal-growth | |
#10 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Larche Mark | 130 |
#2 | Laidler Paul | 125 |
#3 | Hafner Roderick Peter | 118 |
#4 | Layton Guy | 32 |
#5 | Hickey Pascal | 27 |
#6 | Kay Anthony Barrington | 23 |
#7 | Hafner Rod | 19 |
#8 | Farkas Imre | 10 |
#9 | Paul Laidler | 9 |
#10 | Ledger Philip William | 5 |
Publication | Filing date | Title |
---|---|---|
GB201608171D0 | Assay | |
GB201601872D0 | Japanese cedar and japanese cypress peptides for preventing or treating allergy | |
AU2015227499A1 | Compositions with reduced dimer formation | |
AU2013203568A1 | Peptides for desensibilization against allergens | |
AU2013202871A1 | Vaccine peptide combinations against cat allergy | |
AU2013202362A1 | Grass Peptides for Vaccine | |
GB201305926D0 | Japanese cedar and japanese cypress peptides for preventing or treating allergy | |
GB201211585D0 | Japanese cedar and japanese cypress peptides for preventing and treating allergy | |
GB201211586D0 | Japanese cedar peptides for preventing or treating allergy | |
GB201209862D0 | Cladosporium peptides | |
GB201209868D0 | Alternaria peptides | |
GB201208293D0 | Hydrochlorice salt of peptide | |
GB201002559D0 | Birch peptides for vaccine | |
CN103784952A | Peptides for vaccine | |
GB201001624D0 | Peptides for vaccine | |
GB0917871D0 | Peptides for vaccine | |
EP2331124A1 | T-cell antigen peptide from allergen for stimulation of il-10 production | |
GB0912578D0 | Peptide for IL-10 production | |
EP2153841A1 | Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy | |
GB0902344D0 | Peptides for vaccine |